CIRM funds Greenstone Biosciences with $1.35M to accelerate drug discovery using patient-derived induced pluripotent stem cells

Greenstone Biosciences, Inc., a computational biology driven drug discovery company, announces that the Company has received a translational (TRAN4) grant funding from the California Institute of Regenerative Medicine (CIRM) (

Greenstone Bio (Stanford Research Park) focuses on clinical genomics, human induced pluripotent stem cell (iPSC) technology, artificial intelligence / machine learning (AI/ML), and drug development. The Company has extensive knowledge and expertise in generating patient-derived iPSCs and currently possesses the largest patient-derived iPSC Biobank. Greenstone Bio offers iPSC lines to academic collaborators at no cost, with several top institutions partnering to accelerate personalized medicine.

Drugs often fail clinical trials due to lack of safety or efficacy, costing substantial time and money while putting people at risk. “Using iPSCs we can model a patient-specific drug response in a dish”, commented co-founder Dr. Joseph Wu. Dr. Wu is the Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine & Radiology at Stanford University ( By collecting and pooling many iPSCs from individuals of diverse backgrounds, the Company will now streamline a high-throughput method to predict the safety profile of drugs. It can also predict efficacy across different sex, ethnicities, and types of diseases to de-risk clinical trials.

Greenstone Bio Board Chairman, Lip-Bu Tan of Walden Catalyst Venture, is a long-term strategic partner. Mr. Tan considers this award as a “validation of the engine that Greenstone Bio has built to advance translational medicine from bench to bedside.

About Greenstone Biosciences, Inc.

Greenstone Bio is a commercial-stage computational biology company specializing in stem cell technology, artificial intelligence & machine learning, and drug discovery. For further information about the Company, please visit

Greenstone Biosciences, Inc. Contact

Jade Chao, JD

Chief Operating Officer


Back to news